@article {4892,
	title = {Evaluation and Application of Donors with Primary Central Nervous System Tumors},
	volume = {33},
	year = {2019},
	month = {Oct},
	pages = {e13677},
	abstract = {Background: This study aimed to explore the safety of donors with primary central nervous system tumors for kidney and liver transplantations.

Methodology: Clinical data of 29 donors with primary CNS tumors in January 2007 to December 2017, as well as the follow-up data of 16 liver transplant recipients and 46 kidney transplant recipients, were analyzed. According to the risk factors, the high-risk group was classified as Group 1, the low-risk factors were classified as Group 2, and the unknown risk group was classified as Group 3. The incidence of donor-transmitted CNS tumors was calculated and compared.

Results: The duration from the diagnosis of 29 donors to donation was 5.67 {\textpm} 6.36 months. None of the liver and kidney transplant recipients who were followed up had tumor metastasis. Although the mean survival time of Group 1 was lower than that of Group 2 and Group 3, the Kaplan-Meier curve showed no significant difference in survival time.

Conclusion: No obvious difference was observed between high-risk and low-risk and unknown risk CNS tumors in terms of the survival rate of transplants and tumor metastasis rate. High-risk CNS tumor donors can be used with the informed consent of recipients after a full evaluation.},
	author = {Wu, JH and Qiao, PF and Sun, XY and Dong, JH and Liao, JX and Liu, XY and Gao, Z and Lan, LG and Li, HB and Su, QD}
}
